Pancreatic Ductal Adenocarcinoma (PDAC) Clinical Trials in Baltimore, Maryland
7 studies are recruiting for pancreatic ductal adenocarcinoma (pdac) in Baltimore, Maryland right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.
Search these by distance from you
Studies now recruiting
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RMC-5127 as a monotherapy and in combination with either daraxonrasib or cetuximab in adults with KRAS G12V-mutant solid tumors.
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- Johns Hopkins, Baltimore, Maryland
- Locations
- 9 in total
- Run by
- Revolution Medicines, Inc.
-
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
The purpose of this study is to evaluate the safety and efficacy of an investigational RAS(ON) inhibitor administered as monotherapy or in combination with chemotherapy, compared with standard of care (SOC) chemotherapy alone.
- Stage
- Phase 3
- Ages
- 18 and older
- Site
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland
- Locations
- 49 in total
- Run by
- Revolution Medicines, Inc.
-
Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )
The purpose of this study is to evaluate the efficacy of an investigational RAS(ON) inhibitor administered in combination with chemotherapy compared to placebo in combination with chemotherapy.
- Stage
- Phase 3
- Ages
- 18 and older
- Site
- Johns Hopkins University, Baltimore, Maryland
- Locations
- 9 in total
- Run by
- Revolution Medicines, Inc.
-
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab in patients with metastatic KRAS G12D - mutated Pancreatic Cancer
- Stage
- Phase 2
- Ages
- 18 and older
- Site
- Johns Hopkins University, Baltimore, Maryland
- Locations
- 29 in total
- Run by
- Verastem, Inc.
-
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
This study is to evaluate the safety and tolerability of RMC-9805 as monotherapy and in combination with RMC-6236 in adults with KRAS G12D-mutant solid tumors.
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- Johns Hopkins University, Baltimore, Maryland
- Locations
- 17 in total
- Run by
- Revolution Medicines, Inc.
-
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
The purpose of this study is to evaluate the safety, tolerability, and efficacy of BMS-986523 alone and in combination with anti-cancer agents in participants with advanced solid malignancies
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- Johns Hopkins Hospital, Baltimore, Maryland
- Locations
- 8 in total
- Run by
- Bristol-Myers Squibb
-
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- Johns Hopkins University, Baltimore, Maryland
- Locations
- 21 in total
- Run by
- Revolution Medicines, Inc.
How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.
What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.
Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.